Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of deucravacitinib in Crohn's disease and ulcerative colitis
jRCT2031210637Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of deucravacitinib in Crohn's disease and autoimmune colitis, sponsored by Bristol Myers Squibb. Started Mar 2022; status: completed.
02
Drugs
deucravacitinib
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on jRCT2031210637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210637.